trial
as of 2026-07-01Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia
NCTId NCT00546403
at a glance
— · Completed
Enrollment 26 (actual)
Sponsored by Veterans Medical Research Foundation
Primary completion 2008-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
26 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2003-02
Primary completion
2008-02
Eligibility
MALE · 18 Years · 65 Years
Interventions & indications
Sponsors
Veterans Medical Research FoundationLead Sponsor
CephalonCollaborator
Investigators
1
James B Lohr, MD, PhDPrincipal Investigator
Sites
1 total
San Diego, United States
Facts & assertions
4 sourced
Enrollment
26
Phase
NA
Primary Completion Date
2008-02
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
company
indication
investigator
person